Cohen Milstein Seeks Lead In Zimmer Biomet PE Cashout Suit

Law360 (August 15, 2019, 4:34 PM EDT) -- Cohen Milstein Sellers & Toll PLLC told the Delaware Chancery Court it is best suited to serve as lead counsel of two derivative actions that claim Zimmer Biomet's stock prices plummeted after the medical device maker's officers hid compliance problems and helped private equity funds cash out to the tune of billions.

In a brief filed with the court Wednesday, Cohen Milstein said it “has the resources and experience necessary to prosecute this litigation vigorously and effectively” and “is among the most experienced and successful firms in complex stockholder litigation nationwide and has obtained numerous large recoveries on behalf of stockholders.”...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS